GlassScriptPhysician profile
Edward Charles Gnam
NPI 1407944499
$2,870.64
in general payments reported to CMS, 2019-2025
26 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $225 · 2021: $346 · 2022: $704 · 2023: $305 · 2024: $432 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $605.09 | 2019-2023 | |
| Intuitive Surgical, INC. | $554.84 | 2019-2024 | Da Vinci Surgical System |
| Astellas Pharma US INC | $290.70 | 2023-2025 | Veozah |
| Organon LLC | $248.74 | 2021-2025 | Nexplanon, Jada System |
| Pfizer INC. | $155.02 | 2021-2025 | |
| Amgen INC. | $143.29 | 2019-2020 | |
| Davol INC. | $141.43 | 2022-2023 | Arista Ah Flexitip |
| Medtronic, INC. | $127.46 | 2022-2023 | Interstim |
| Hologic Sales and Service, LLC | $75.87 | 2019-2025 | Myosure Tissue Removal Device, Novasure |
| Heron Therapeutics, INC. | $67.39 | 2024 | Zynrelef |
| Mayne Pharma Commercial LLC | $59.15 | 2025 | |
| Coopersurgical, INC. | $53.49 | 2019-2020 | |
| Daiichi Sankyo INC. | $52.26 | 2022 | |
| Therapeuticsmd, INC. | $44.97 | 2020-2021 | |
| Shield Therapeutics INC | $33.51 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $30.96 | 2021-2022 | |
| Inari Medical, INC. | $28.99 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Avion Pharmaceuticals | $26.18 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.83 | 2022 | |
| Allergan, INC. | $23.75 | 2020 | |
| Sage Therapeutics, LLC | $15.52 | 2024 | |
| Boston Scientific Corporation | $15.22 | 2021 | |
| Merck Sharp & Dohme LLC | $13.85 | 2019 | |
| Smith+Nephew, INC. | $13.17 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.56 | 2021 | |
| Myovant Sciences INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Gnam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.